Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Wacker to produce COVID-19 vaccine for CureVac

by Alex Scott
November 28, 2020 | A version of this story appeared in Volume 98, Issue 46

 

A photo of Wacker's Amsterdam facility.
Credit: Wacker Chemie
Wacker's Amsterdam facility

Wacker Chemie is one of several European firms to secure a contract to supply ribonucleic acid for CureVac’s COVID-19 vaccine candidate, CVnCoV. Wacker has capability to produce more than 100 million doses per year of CVnCoV at its facility in Amsterdam. The vaccine, which CureVac began developing in January, is in Phase 2 trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.